King Pharmaceuticals, a subsidiary of Pfizer, announced a voluntary recall of all lots of Embeda (morphine/naltrexone extended-release capsules) because Embeda did not meet a prespecified stability requirement during routine testing. Based on available data, the manufacturer states that this issue is unlikely to cause adverse health consequences to patients using Embeda as prescribed by their physicians. Until this issue is resolved, Embeda will not be available.  

Embeda is a C-II controlled substance indicated for moderate to severe pain management when a continuous, around-the-clock opioid is needed for an extended time period.

For more information call (800) 776-3637 or visit